Takeda Pharmaceutical Company Limited, The Current Fiscal Year Net Income Revised Upward by 17%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Thu Oct 31, 2024 3:00 pm JST Earnings

4502 Takeda Pharmaceutical Company Limited 【IFRS】

Earnings Report

Takeda Pharmaceutical Company Limited <4502> [TSE-P] announced its financial results (based on IFRS) after the market closed on October 31st (15:00). The consolidated net income for the cumulative second quarter of the fiscal year ending March 2025 (April to September) surged by 4.5 times that of the same period last year, reaching 187 billion yen.

In addition, the full-year consolidated net income has been revised upward by 17.2%, from the previous forecast of 58 billion yen to 68 billion yen (compared to 144 billion yen in the previous period), and the declining rate is expected to decrease from 59.7% to 52.8%.

Based on the first-half performance announced by the company and the full-year plan, our calculation indicates that the consolidated net income/loss for the October to March period (second half) is expected to turn into a loss of 119 billion yen (compared to a profit of 102 billion yen in the same period last year).

In the most recent three-month period, from July to September (2Q), the consolidated net income/loss turned to a profit of profit of 92 billion yen (compared to a loss of 48 billion yen in the same period last year). The operating profit/loss margin drastically improved from -4.7% in the same period last year to 15.7%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	1,974,771	254,953	220,022	166,756	107.6	58.7	Oct 27, 2022	IFRS
Apr - Sep, 2023	2,101,707	119,230	39,053	41,365	26.5	74.0	Oct 26, 2023	IFRS
Apr - Sep, 2024	2,384,028	350,576	255,976	187,294	118.9	275.2	Oct 31, 2024	IFRS
YoY	+13.4%	+194.0%	+555.5%	+352.8%	+348.3%

First Half Results vs. Previous Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2024 Guidance	ー	ー	ー	ー	－	98	May 9, 2024	IFRS
Apr - Sep, 2024 Results	2,384,028	350,576	255,976	187,294	118.9	98	Oct 31, 2024	IFRS
Revision Rate	－	－	－	－	－

Guidance Update

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	4,350,000	225,000	55,000	58,000	36.6	196	May 9, 2024	IFRS
Mar, 2025 New	4,480,000	265,000	93,000	68,000	42.9	196	Oct 31, 2024	IFRS
Revision Rate	+3.0%	+17.8%	+69.1%	+17.2%	+17.2%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	2,162,055	94,845	13,738	102,702	65.7	94	May 9, 2024	IFRS
Oct - Mar, 2024 Guidance	2,095,972	-85,576	-162,976	-119,294	-75.3	98	Oct 31, 2024	IFRS
YoY	-3.1%	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	4,027,478	490,505	375,090	317,017	204.3	180	May 11, 2023	IFRS
Mar, 2024	4,263,762	214,075	52,791	144,067	92.1	188	May 9, 2024	IFRS
Mar, 2025 Guidance	4,480,000	265,000	93,000	68,000	42.9	196	Oct 31, 2024	IFRS
YoY	+5.1%	+23.8%	+76.2%	-52.8%	-53.4%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jul - Sep, 2023	1,043,089	-49,341	-95,980	-48,030	-30.8	-4.7	Oct 26, 2023	IFRS
Oct - Dec, 2023	1,111,186	104,914	61,260	105,720	67.6	9.4	Feb 1, 2024	IFRS
Jan - Mar, 2024	1,050,869	-10,069	-47,522	-3,018	-1.9	-1.0	May 9, 2024	IFRS
Apr - Jun, 2024	1,207,990	166,329	136,604	95,248	60.7	13.8	Jul 31, 2024	IFRS
Jul - Sep, 2024	1,176,038	184,247	119,372	92,046	58.4	15.7	Oct 31, 2024	IFRS
YoY	+12.7%	－	－	－	－